As of 2026-10-02, the EV/EBITDA ratio of 10X Genomics Inc (TXG) is -191.87. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TXG's latest enterprise value is 10,766.46 mil USD. TXG's TTM EBITDA according to its financial statements is -56.11 mil USD. Dividing these 2 quantities gives us the above TXG EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 17.6x - 25.6x | 21.6x |
| Forward P/E multiples | 29.8x - 40.3x | 37.0x |
| Fair Price | (3.83) - 5.62 | (0.06) |
| Upside | -104.3% - -93.7% | -100.1% |
| Date | EV/EBITDA |
| 2026-10-01 | -191.87 |
| 2026-09-30 | -195.49 |
| 2026-09-29 | -194.77 |
| 2026-09-28 | -191.29 |
| 2026-09-25 | -184.97 |
| 2026-09-24 | -181.35 |
| 2026-09-23 | -162.14 |
| 2026-09-22 | -173.64 |
| 2026-09-21 | -170.02 |
| 2026-09-18 | -164.36 |
| 2026-09-17 | -165.20 |
| 2026-09-16 | -155.49 |
| 2026-09-15 | -159.36 |
| 2026-09-14 | -149.68 |
| 2026-09-11 | -146.24 |
| 2026-09-10 | -141.24 |
| 2026-09-09 | -143.30 |
| 2026-09-08 | -139.47 |
| 2026-09-04 | -132.80 |
| 2026-09-03 | -134.09 |
| 2026-09-02 | -130.53 |
| 2026-09-01 | -126.76 |
| 2026-08-31 | -132.34 |
| 2026-08-28 | -130.29 |
| 2026-08-27 | -137.78 |
| 2026-08-26 | -136.44 |
| 2026-08-25 | -137.48 |
| 2026-08-24 | -135.40 |
| 2026-08-21 | -138.39 |
| 2026-08-20 | -135.56 |
| 2026-08-19 | -131.76 |
| 2026-08-18 | -116.91 |
| 2026-08-17 | -122.25 |
| 2026-08-14 | -117.95 |
| 2026-08-13 | -122.62 |
| 2026-08-12 | -121.71 |
| 2026-08-11 | -123.36 |
| 2026-08-10 | -123.57 |
| 2026-08-07 | -108.77 |
| 2026-08-06 | -94.22 |
| 2026-08-05 | -98.43 |
| 2026-08-04 | -99.33 |
| 2026-08-03 | -97.41 |
| 2026-07-31 | -98.00 |
| 2026-07-30 | -102.89 |
| 2026-07-29 | -95.85 |
| 2026-07-28 | -97.50 |
| 2026-07-27 | -94.94 |
| 2026-07-24 | -95.74 |
| 2026-07-23 | -99.79 |